Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | CASR | P41180 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 3/20 | 0.35 |
| ▸ | MMP7 | P09237 | 3/20 | 0.35 |
| ▸ | MMP12 | P39900 | 3/20 | 0.35 |
| ▸ | MMP13 | P45452 | 3/20 | 0.35 |
| ▸ | ACE | P12821 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3928059 | 0.95 | SLC7A5 (0.40) | POLBALDH1A1KDM4ESLC7A5CNR2 | |
| SCHEMBL6716961 | 0.93 | ALDH1A1 (0.40) | POLBALDH1A1SLC7A5CNR2NAAA | |
| SCHEMBL6723179 | 0.93 | ALDH1A1 (0.40) | POLBALDH1A1SLC7A5CNR2NAAA | |
| SCHEMBL1432767 | 0.89 | AOC3 (0.39) | POLBSLC6A4CYP3A4LMNASMN1; SMN2 | |
| SCHEMBL11005234 | 0.85 | HRH3 (0.39) | CA2 | |
| SCHEMBL27372 | 0.82 | LMNA (0.42) | POLBALDH1A1KDM4ESLC7A5SLC6A4 | |
| SCHEMBL9572521 | 0.82 | AOC3 (0.43) | CASRSLC6A4MMP1MMP7MMP12 | |
| SCHEMBL7453749 | 0.80 | POLB (0.44) | POLBALDH1A1KDM4ESLC7A5CASR | |
| SCHEMBL3168356 | 0.79 | CYP1A2 (0.36) | POLBSLC6A4CYP3A4LMNASMN1; SMN2 | |
| SCHEMBL6254117 | 0.78 | POLB (0.42) | POLBALDH1A1KDM4ESLC7A5CASR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210309619-A1 | ISOXAZOLIN-5-ONE DERIVATIVES AND HERBICIDES CONTAINING THE SAME AS ACTIVE INGREDIENTS | HOKKO CHEMICAL INDUSTRY CO., LTD. (JP) | 2021-10-07 | — | — | US | disclosed |
| US-11109593-B2 | Isoxazolin-5-one derivative and herbicide containing same as active ingredient | HOKKO CHEMICAL INDUSTRY CO., LTD. (JP) | 2021-09-07 | — | — | US | disclosed |
| EP-3828176-A1 | ISOXAZOLIN-5-ONE DERIVATIVE, AND HERBICIDE CONTAINING SAME AS ACTIVE INGREDIENT | Hokko Chemical Industry Co., Ltd. (JP) | 2021-06-02 | — | — | EP | disclosed |
| US-20200267985-A1 | ISOXAZOLIN-5-ONE DERIVATIVE AND HERBICIDE CONTAINING SAME AS ACTIVE INGREDIENT | HOKKO CHEMICAL INDUSTRY CO., LTD. (JP) | 2020-08-27 | — | — | US | disclosed |
| WO-2020022350-A1 | ISOXAZOLIN-5-ONE DERIVATIVE, AND HERBICIDE CONTAINING SAME AS ACTIVE INGREDIENT | 北興化学工業株式会社 | 2020-01-30 | — | — | WO | disclosed |
| CN-110191880-A | Isoxazolidin-5-one derivative and herbicide containing the same as active ingredient | 北兴化学工业株式会社 | 2019-08-30 | — | — | CN | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
| US-6645671-B2 | Suppressing reaction between organic solvent and anode via imide compound which coordinates with lithium ions quickly and strongly, improving cycling; power sources for memory retention in electronics | FUJITSU LIMITED (JP) | 2003-11-11 | — | — | US | disclosed |
| EP-1158589-A1 | SECONDARY LITHIUM BATTERY, NEGATIVE ELECTRODE FOR SECONDARY LITHIUM BATTERY, AND PROCESS FOR PRODUCING THE NEGATIVE ELECTRODE | FUJITSU LIMITED (JP) | 2001-11-28 | — | — | EP | disclosed |
| US-20010031396-A1 | Lithium secondary battery, anode for lithium secondary battery, and method for manufacturing the anode | FUJITSU LIMITED (JP) | 2001-10-18 | — | — | US | disclosed |
| US-5998065-A | N-OXYIMIDE ADDITIVE | FUJITSU LIMITED (JP) | 1999-12-07 | — | — | US | disclosed |
| EP-0562832-A1 | Indole and indazole derivatives, for the treatment and prophylaxis of cerebral disorders, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1993-09-29 | — | — | EP | disclosed |
| US-4539151-A | Benzothiazepine derivatives and their method of preparation | MITSUI TOATSU CHEMICALS, INC. (JP) | 1985-09-03 | — | — | US | disclosed |
| US-4539150-A | HYPOTENSIVE AGENTS, SULFIDING, CYCLIZATION | MITSUI TOATSU CHEMICALS, INC. (JP) | 1985-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200267985-A1 | ISOXAZOLIN-5-ONE DERIVATIVE AND HERBICIDE CONTAINING SAME AS ACTIVE INGREDIENT | HAX1, CYP4X1, CANX | POLB 4398/4885ALDH1A1 852/4885KDM4E 2850/4885 |
| US-11109593-B2 | Isoxazolin-5-one derivative and herbicide containing same as active ingredient | HAX1, CYP4X1, CANX | POLB 4398/4885ALDH1A1 852/4885KDM4E 2850/4885 |
| US-20210309619-A1 | ISOXAZOLIN-5-ONE DERIVATIVES AND HERBICIDES CONTAINING THE SAME AS ACTIVE INGREDIENTS | HAX1, CYP4X1, CNPY2 | POLB 3724/4885ALDH1A1 795/4885KDM4E 3492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.